We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novo Nordisk Halts Hemophilia Drug’s Development, Three Others Remain
Novo Nordisk Halts Hemophilia Drug’s Development, Three Others Remain
October 5, 2012
Novo Nordisk has discontinued development of one of its four hemophilia drug candidates following data from a Phase IIIa trial that found anti-drug antibodies and further potential risks for hemophilia patients with inhibitors.